A phase Ib study reported personalized neoantigen-pulsed autologous dendritic cell vaccination in newly diagnosed glioblastoma. Published in Nature Communications, the trial evaluates individualized neoantigen dendritic cell therapy to support immune priming in patients at diagnosis, targeting improved survival and disease control through patient-specific antigen selection.